"The Report Global
Human Respiratory Syncytial Virus Drugs Market 2016-2020 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
MarketResearchReport.biz
has announced the addition of a market intelligence report, titled
“Global
Human Respiratory Syncytial Virus Drugs Market
2016-2020,” to its wide repository. The report offers an immaculate
understanding of the various parameters of the market, including its
dynamics, competitive scenario, drug category, geographical
segmentation.
As
per the findings of the report, the global human respiratory
syncytial virus (RSV) drugs market is expected to expand at a steady
CAGR of more than 4% from 2016 to 2020. The growing adoption of novel
diagnostic tools is fostering the growth prospects of the market. The
soaring need for accurate diagnosis is paving way for increased
research and development of new and effective diagnostic tools. Some
of the novel diagnostic methods are RT-PCR assays, rapid diagnostic
assays, and serological tests. Moreover, the expanding base of
patient population suffering from RSV is providing a significant
boost to the growth of the market.
On
the other hand, the protean healthcare guidelines are negatively
impacting the growth of the market. Furthermore, the availability of
a limited number of drugs is leading to low penetration rates, which
in turn is hampering the growth of the market. Nevertheless, the
increasing research activities in emerging economies for the
development of novel RSV drugs are likely to augment the market in
the near future.
Get Sample Copy Of This
Report @
Based
on drug category, the global human RSV drugs market is bifurcated
into off-label drugs and approved drugs. Approved drugs will
represent a larger share in the revenue pie in the market throughout
the forecast period. The expected launch of several biologics such as
RNAi therapeutics, vaccines, and monoclonal antibodies. On the basis
of geography, the market is divided into Europe, the U.S., and Rest
of the World (RoW). The RoW segment will continue to account for the
lion’s share in the market in terms of revenue until 2020. The
increasing prevalence of RSV infections and the improving healthcare
infrastructure in emerging countries such as India, Brazil, China,
and South Africa.
Vendors
offering Synagis in their respective markets are typically the major
revenue contributors in the global human respiratory syncytial virus
drugs market. Mergers and acquisitions are commonly adopted
strategies by key players to improve their pipelines and consolidate
their presence in the market. Several players are paying high
attention to research and development activities in order to
introduce RSV vaccines for individuals above 60 years of age.
View Press Release @
The
leading players in the global human RSV drugs market are GSK, Abbvie,
Teva Pharmaceutical, and AstraZeneca. Some other prominent companies
operating in the market are ADMA Biologics, Ark Biosciences,
Boehringer Ingelheim, Aviragen Therapeutics, ImmunoVaccine
Technologies, Kyowa Hakko Kirin, Johnson & Johnson, Medivir,
Mymetics, Mucosis, Regeneron Pharmaceuticals, Novavax, ReViral, and
Vaxart.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment